GSK (NYSE:GSK) Downgraded to Buy Rating by StockNews.com

GSK (NYSE:GSK) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

Several other research firms have also recently weighed in on GSK. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Price Performance

Shares of GSK stock opened at $33.44 on Tuesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. GSK has a 52-week low of $31.72 and a 52-week high of $45.92. The stock has a market cap of $69.30 billion, a PE ratio of 21.71, a PEG ratio of 1.47 and a beta of 0.63. The firm’s 50 day moving average price is $33.93 and its two-hundred day moving average price is $37.90.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its position in shares of GSK by 33.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,256,320 shares of the pharmaceutical company’s stock worth $86,875,000 after purchasing an additional 569,614 shares during the period. AE Wealth Management LLC lifted its holdings in shares of GSK by 4.3% during the second quarter. AE Wealth Management LLC now owns 19,869 shares of the pharmaceutical company’s stock worth $765,000 after purchasing an additional 815 shares during the period. Sei Investments Co. boosted its holdings in GSK by 3.1% in the second quarter. Sei Investments Co. now owns 831,592 shares of the pharmaceutical company’s stock valued at $32,017,000 after acquiring an additional 24,658 shares during the last quarter. Summit Trail Advisors LLC raised its stake in GSK by 37.2% during the second quarter. Summit Trail Advisors LLC now owns 7,473 shares of the pharmaceutical company’s stock worth $290,000 after buying an additional 2,027 shares during the last quarter. Finally, Profund Advisors LLC increased its holdings in GSK by 3.0% in the second quarter. Profund Advisors LLC now owns 14,979 shares of the pharmaceutical company’s stock worth $577,000 after purchasing an additional 433 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.